A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin

Author:  ["J Stech","H Garn","M Wegmann","R Wagner","H-D Klenk"]

Publication:  Nature Medicine

CITE.CC academic search helps you expand the influence of your papers.

Tags:     Medicine

Abstract

A promising approach to reduce the impact of influenza is the use of an attenuated, live virus as a vaccine. Using reverse genetics, we generated a mutant of strain A/WSN/33 with a modified cleavage site within its hemagglutinin, which depends on proteolytic activation by elastase. Unlike the wild-type, which requires trypsin, this mutant is strictly dependent on elastase. Both viruses grow equally well in cell culture. In contrast to the lethal wild-type virus, the mutant is entirely attenuated in mice. At a dose of 105 plaque-forming units, it induced complete protection against lethal challenge. This approach allows the conversion of any epidemic strain into a genetically homologous attenuated virus.

Cite this article

Stech, J., Garn, H., Wegmann, M. et al. A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin. Nat Med 11, 683–689 (2005). https://doi.org/10.1038/nm1256

View full text

>> Full Text:   A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice